Cancer clinical trials in the region Bourgogne-Franche-Comté

206 currently recruiting clinical trials
Region Bourgogne-Franche-Comté

Early Access Head and neck cancer
Required histologic types
Oral cavity Nasopharynx Oropharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
1 recruiting site
Merck Sharp & Dohme LLC
Early Access Lung cancer
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Amgen
Early Access Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Early Access Brain tumors / Central nervous system tumors
Required histologic types
Gliomas
Required histologic sub types
Astrocytoma grade II Oligodendroglioma grade II
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive Surgery
1 recruiting site
Servier
Early Access Stomach and esophageal cancer
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Daiichi Sankyo
Early Access Lymphoma
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
1
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access Breast cancer
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access Lung cancer
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Chemotherapy Radiotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
1 recruiting site
AstraZeneca
Early Access Lung cancer
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access Stomach and esophageal cancer
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
AstraZeneca